Myelodysplastic syndrome with excess blasts-2
MONDO:0015041A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and <10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)
Also known as: MDS-EB-2, RAEB-2, RAEB-II, myelodysplastic syndrome with Excess blasts-2, refractory anaemia with excess blasts type 2, refractory anemia with excess blasts type 2
1861 clinical trials for this condition and its sub-types, 12 tagged with Myelodysplastic syndrome with excess blasts-2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Early phase 1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail takes aim at stubborn leukemia
Disease control OngoingThis early-phase trial is testing whether adding an experimental drug called Q702 to two standard leukemia drugs (azacitidine and venetoclax) is safe for people with relapsed or refractory acute myeloid leukemia (AML). About 17 adults whose leukemia has not responded to or has re…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC